HHS Announces Funding for Ibogaine and Rapid-Acting Psychotropic Research
Key Clinical Summary:
- HHS announced up to $4.9 million over 5 years through ARPA-H to support ibogaine development for PTSD and other serious mental illnesses, including preparations for future US trials and domestic manufacturing.
- ARPA-H funding does not support patient treatment or human-subject research or authorize clinical trials, and continued funding depends on meeting research milestones.
- NIMH announced a $20 million funding opportunity for studying rapid-acting psychotropic treatments, including ketamine, esketamine, and psilocybin, with award recipients to be announced in summer 2027.
US Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. announced on November 12, 2026, investments of up to $4.9 million to advance the development of ibogaine as a potential treatment for posttraumatic stress disorder (PTSD) and other serious mental illnesses.
The investment through the Advanced Research Projects Agency for Health (ARPA-H) supports preparations for future US-based clinical ibogaine trials, securing clinical-grade ibogaine, and developing infrastructure for domestic manufacturing of the psychedelic agent. While the funding aims to set the groundwork for future domestic clinical research, it does not fund patient treatment or human-subject research or authorize clinical trials.
National Institute of Mental Health (NIMH) Acting Director Andrea Beckel-Mitchener, PhD, also announced the publication of a $20 million Notice of Funding Opportunity (NOFO) to establish a research network focused on rapid-acting psychotropic interventional drugs including ketamine, esketamine, and psilocybin.
Ibogaine Development and Veterans’ Mental Health
“Yesterday on Veterans Day, Americans recognized the service of our military veterans,” Kennedy said during a press conference announcing the initiative. “Our responsibility includes investing in research that could improve their care and give vets accurate information about potential treatment.”
The announcement comes in the wake of President Donald J. Trump’s April 18, 2026, executive order, “Accelerating Medical Treatments for Serious Mental Illness,” supporting the development and research of psychedelic therapies for psychiatric illness. The order also authorized $50 million in federal funding to support a Texas ibogaine research initiative, a component of which evaluates the drug specifically in veterans.
Kennedy also announced that HHS secured an agreement to obtain clinical data from Beond Inc., a Texas-based company operating an ibogaine clinic in Mexico. The shared data will allow for further evaluation of the drug’s safety, efficacy, dosing, and tolerability, and will “dramatically accelerate the clinical trial process,” according to Kennedy.
“We’re going to have, I think, a record drug approval process,” he said, though he emphasized that all drug applications would undergo the same rigorous research and assessment.
NIMH Funds Research Network for Rapid-Acting Treatments
Beckel-Mitchener said that the NIMH research investment aims to guide the safe and sustainable use of rapid-acting psychotropic treatments, including newer agents that may receive US Food and Drug Administration (FDA) approval.
“Initially, we’re hoping to support a data coordination center so we can harmonize all the data that are collected across the studies,” she said, with a focus on trials in real-world settings.
The initiative hopes to inform models for optimal health care uptake, service delivery, training, and workforce demands if newer agents are approved. Other research priorities include the utility of adjunctive treatment and optimal retreatment frequency.
Looking Ahead
Beckel-Mitchener said NIMH will award $10 million in this fiscal year and $10 million in the next fiscal year, with award recipients announced in the summer of 2027.
Meanwhile, ARPA-H’s commitment will be invested over 5 years, with continued funding contingent on meeting research milestones. Additional awards are expected to evaluate ibogaine as a treatment for substance use disorders (SUDs).
Research teams led by the Mark Cuban Cost Plus Drug Company will establish the regulatory and clinical foundation for a domestically manufactured, single-molecule ibogaine hydrochloride product. If the drug receives FDA approval, Kennedy claims there will be an effort to ensure the cost is similar to that of other generic medications.
In a press release, HHS also emphasized that ibogaine carries serious safety risks, including potentially life-threatening heart rhythm problems, underscoring the need for future research to address participant screening, cardiac monitoring, and independent safety oversight.
